摘要
目的比较在Gal抗原缺失小鼠皮下分别植入GGTA1/B4GalNT2/CMAH基因敲除猪软骨组织与野生型猪软骨组织所引起的免疫反应。方法将三基因敲除猪软骨组织(KO组)与野生型猪软骨组织(WT组)分别植入Gal抗原缺失小鼠皮下4周,设立假手术组(con)作为阴性对照。4周后抽取小鼠血清检测总IgM抗体和抗Gal抗体。结果野生型猪软骨(WT)材料植入组小鼠总IgM含量平均在(0.525±0.224)mg/ml,显著高于阴性对照(Con)组小鼠总IgM平均含量(0.121±0.050)mg/ml(P<0.05),但与三基因敲除猪软骨(KO)组小鼠总IgM平均含量(0.313±0.061)mg/ml无统计学差异。野生型猪软骨组织具有比三基因敲除猪软骨组织组和对照组更高的抗α-Gal IgM水平(P<0.05),而三基因敲除组与对照组相比无统计学差异(P>0.05)。结论上述结果表明GGTA1/B4GalNT2/CMAH基因敲除猪软骨组织在体内几乎没有免疫反应,可作为软骨缺损修复材料。
Objective To compare the immune responses induced by GGTA1/B4 GalNT2/CMAH knockout pig cartilage tissue versus wild-type pig cartilage tissue in Gal antigen-deficient mice.Methods The GGTA1/B4 GalNT2/CMAH gene-knockout pig cartilage tissue(KO)or wild type pig cartilage tissue(WT)was implanted subcutaneously into GGTA1 knockout mice for 4 weeks,respectively.And sham operation group(con)was set as negative control.After 4 weeks,mice serum was taken to detect total IgM antibody and anti-Gal antibody.Results The total IgM content of mice in the WT group was 0.525±0.224 mg/ml,significantly higher than that in the con group(0.121±0.050 mg/ml,P<0.05),but had no difference with KO group(0.313±0.061 mg/ml,P>0.05).Anti-α-Gal IgM level was significantly higher in WT group than KO group and control group(P<0.05,respectively),while no significant difference was found between KO and control group(P>0.05).Conclusion The results indicate that GGTA1/B4 GalNT2/CMAH gene-knockout pig cartilage tissue induces little immune response in vivo and can be used as cartilage defect repairing materials.
作者
王泽昊
邵安良
魏利娜
刘舒云
眭翔
徐丽明
郭全义
WANG Zehao;SHAO Anliang;WEI Lina;LIU Shuyun;SUI Xiang;XU Liming;GUO Quanyi(institute of Orthopedics,Beijing Key Lab of Regenerative Medicine in Orthopedics,Key Laboratory of Musculoskeletal Trauma &War Injuries,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China;institute for Medical Device Control,National Institutes for Food and Drug Control,Beijing 102629,China)
出处
《解放军医学院学报》
CAS
2019年第6期561-564,共4页
Academic Journal of Chinese PLA Medical School
基金
国家重点研发计划(2018YFC1105901
2017YFC1103404)
国家自然科学基金项目(81177090032)
北京市自然科学基金项目(7172203)
解放军总医院转化项目(2017TM-014)~~
